Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
Sponsor: Fundación GECP
Terminated
Low recruitment
Other EGFR Gene Mutation trials with similar outcome
A PHASE2 clinical study on EGFR Gene Mutation and Non Small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Fundación GECP and has accumulated 14 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Feb 2025 — May 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jul 2022 — Jul 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jun 2022 [monthly]
Recruiting PHASE2
-
May 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fundación GECP
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Badalona, Spain , Barcelona, Spain , Girona, Spain , Jaén, Spain , L'Hospitalet de Llobregat, Spain , Las Palmas de Gran Canaria, Spain , Lugo, Spain , Madrid, Spain , Majadahonda, Spain and 7 more locations